3,4,5,6-四甲基吡啶-2-胺 | 875-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3,4,5,6-四甲基吡啶-2-胺
• 英文名称: 2-Amino-3,4,5,6-tetramethyl-pyridin
• 英文别名: Pyridine, 2-amino-3,4,5,6-tetramethyl-；3,4,5,6-tetramethylpyridin-2-amine
• CAS: 875-39-8
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: ZAYKXJMWNWERQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics, Inc.

  公开号：US20180105526A1

  公开（公告）日：2018-04-19

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组成物和使用方法。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20090124625A1

  公开（公告）日：2009-05-14

  The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及化合物的新型配方（I），其中W，n，X和W′在说明书中定义；发明的化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20120277237A1

  公开（公告）日：2012-11-01

  The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及一种新型化合物，其化学式为I，其中W、n、X和W′在说明中有定义；发明化合物是代谢型谷氨酸受体-亚型5（“mGluR5”）的调节剂，可用于治疗中枢神经系统疾病以及其他受mGluR5受体调节的疾病。
• IMIDAZOPYRIDINE DERIVATIVES
  申请人：Kumar Sanjay

  公开号：US20120232072A1

  公开（公告）日：2012-09-13

  The present invention relates to compounds of formula (I), wherein R a , R b , R c , R d , R e and R f are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR), Signal transducer and activator of transcription 3 (STAT 3), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) or a combination thereof particularly in the treatment of cancer and inflammation.

  本发明涉及式（I）的化合物，其中Ra，Rb，Rc，Rd，Re和Rf如规范中所定义，它们的制备方法，包含它们的制药组合物以及它们在治疗由磷脂酰肌醇-3-激酶（PI3K），雷帕霉素靶蛋白酶（mTOR），信号转导和转录激活因子3（STAT 3），肿瘤坏死因子-α（TNF-α），白细胞介素-6（IL-6）或其组合介导的疾病特别是在癌症和炎症治疗中的用途。
• Amphiphilic Block Copolymer And Preparation Method Thereof And Micellar Drug-Loading System Formed By Same With Antitumor Drug
  申请人：LIU Ke

  公开号：US20150283246A1

  公开（公告）日：2015-10-08

  The present invention relates to a novel amphiphilic block copolymer and the preparation method thereof, as well as a micellar drug-loaded system formed by said copolymer and an anti-tumor drug. Said amphiphilic block copolymer comprises a hydrophilic segment and a hydrophobic segment, and the end group of said hydrophobic segment is end-capped with a hydrophobic group. Methoxypolyethylene glycol (or polyethylene glycol)-polyester block copolymer which has recognized safety is used as a fundamental material of the amphiphilic block copolymer of the present invention, and the terminal hydroxyl group of the polyester segment is modified with a hydrophobic group, whereby the compatibility between the drug molecule and the hydrophobic segments of the block copolymer is improved, and the interaction therebetween is enhanced. Moreover, a larger space for accommodating the drug molecules is provided. Said micelles are more effective in restricting the drug molecules inside the micellar core and preventing the drug from dissolved out of the micelles. Therefore, a drug-loaded micelle with high stability is obtained.

  本发明涉及一种新型的两亲性嵌段共聚物及其制备方法，以及由该共聚物和抗肿瘤药物形成的微胶束药物载药系统。该两亲性嵌段共聚物包括亲水性段和疏水性段，疏水性段的末端基团被疏水基团封端。本发明的两亲性嵌段共聚物的基础材料采用了已经被认可为安全的甲氧基聚乙二醇（或聚乙二醇）-聚酯嵌段共聚物，并且聚酯段的末端羟基被疏水基团修饰，从而提高了药物分子与嵌段共聚物的疏水性段之间的相容性和相互作用，同时提供了更大的容纳药物分子的空间。这些微胶束更有效地限制了药物分子在微胶束核心内的扩散和溶解，因此获得了高稳定性的药物载药微胶束。